| Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis L Ouyang, Z Shi, S Zhao, FT Wang, TT Zhou, B Liu, JK Bao Cell proliferation 45 (6), 487-498, 2012 | 1805 | 2012 |
| Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery L Fu, M Tian, X Li, J Li, J Huang, L Ouyang, Y Zhang, B Liu Oncotarget 6 (8), 5501, 2015 | 241 | 2015 |
| Plant natural compounds: targeting pathways of autophagy as anti‐cancer therapeutic agents X Zhang, LX Chen, L Ouyang, Y Cheng, B Liu Cell proliferation 45 (5), 466-476, 2012 | 196 | 2012 |
| An overview of Sirtuins as potential therapeutic target: Structure, function and modulators Y Wang, J He, M Liao, M Hu, W Li, H Ouyang, X Wang, T Ye, Y Zhang, ... European journal of medicinal chemistry 161, 48-77, 2019 | 187 | 2019 |
| Targeting autophagy-related protein kinases for potential therapeutic purpose H Xiang, J Zhang, C Lin, L Zhang, B Liu, L Ouyang Acta Pharmaceutica Sinica B 10 (4), 569-581, 2020 | 173 | 2020 |
| Plant natural products: from traditional compounds to new emerging drugs in cancer therapy L Ouyang, Y Luo, M Tian, SY Zhang, R Lu, JH Wang, R Kasimu, X Li Cell proliferation 47 (6), 506-515, 2014 | 158 | 2014 |
| Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment S Ruan, R Xie, L Qin, M Yu, W Xiao, C Hu, W Yu, Z Qian, L Ouyang, Q He, ... Nano letters 19 (11), 8318-8332, 2019 | 148 | 2019 |
| Plant lectins, from ancient sugar‐binding proteins to emerging anti‐cancer drugs in apoptosis and autophagy QL Jiang, S Zhang, M Tian, SY Zhang, T Xie, DY Chen, YJ Chen, J He, ... Cell proliferation 48 (1), 17-28, 2015 | 137 | 2015 |
| Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo L Zhang, L Fu, S Zhang, J Zhang, Y Zhao, Y Zheng, G He, S Yang, ... Chemical science 8 (4), 2687-2701, 2017 | 136 | 2017 |
| Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer Y Shu, W Zhang, Q Hou, L Zhao, S Zhang, J Zhou, X Song, Y Zhang, ... Nature communications 9 (1), 2447, 2018 | 120 | 2018 |
| Tumor microenvironment‐responsive dual drug dimer‐loaded pegylated bilirubin nanoparticles for improved drug delivery and enhanced immune‐chemotherapy of breast cancer X Yang, C Hu, F Tong, R Liu, Y Zhou, L Qin, L Ouyang, H Gao Advanced Functional Materials 29 (32), 1901896, 2019 | 106 | 2019 |
| Review of natural product databases T Xie, S Song, S Li, L Ouyang, L Xia, J Huang Cell proliferation 48 (4), 398-404, 2015 | 101 | 2015 |
| The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy Y Liu, X Wang, G Wang, Y Yang, Y Yuan, L Ouyang European journal of medicinal chemistry 176, 92-104, 2019 | 100 | 2019 |
| Discovery of a small-molecule bromodomain-containing protein 4 (BRD4) inhibitor that induces AMP-activated protein kinase-modulated autophagy-associated cell death in breast cancer L Ouyang, L Zhang, J Liu, L Fu, D Yao, Y Zhao, S Zhang, G Wang, G He, ... Journal of medicinal chemistry 60 (24), 9990-10012, 2017 | 99 | 2017 |
| New techniques and strategies in drug discovery J Du, J Guo, D Kang, Z Li, G Wang, J Wu, Z Zhang, H Fang, X Hou, ... Chinese Chemical Letters 31 (7), 1695-1708, 2020 | 96 | 2020 |
| Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs J Zhang, X Jiang, Y Jiang, M Guo, S Zhang, J Li, J He, J Liu, J Wang, ... European journal of medicinal chemistry 108, 495-504, 2016 | 86 | 2016 |
| Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy L Zhang, J Li, L Ouyang, B Liu, Y Cheng Cancer letters 373 (1), 19-26, 2016 | 85 | 2016 |
| Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy W Shuai, G Wang, Y Zhang, F Bu, S Zhang, DD Miller, W Li, L Ouyang, ... Journal of Medicinal Chemistry 64 (12), 7963-7990, 2021 | 82 | 2021 |
| Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers T Jiang, G Wang, Y Liu, L Feng, M Wang, J Liu, Y Chen, L Ouyang Acta Pharmaceutica Sinica B 11 (2), 355-372, 2021 | 81 | 2021 |
| Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development P Tang, J Zhang, J Liu, CM Chiang, L Ouyang Journal of medicinal chemistry 64 (5), 2419-2435, 2021 | 80 | 2021 |
Xiangrong SongSichuan University在 scu.edu.cn 的电子邮件经过验证
